# Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature

> **NCT03061539** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **University College, London** · enrollment: 380 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Nivolumab & Ipilimumab

## Key facts

- **NCT ID:** NCT03061539
- **Lead sponsor:** University College, London
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-02-06
- **Primary completion:** 2022-06-20
- **Final completion:** 2027-06
- **Target enrollment:** 380 (ACTUAL)
- **Last updated:** 2022-09-28

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03061539

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03061539, "Nivolumab and Ipilimumab Treatment in Prostate Cancer With an Immunogenic Signature". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT03061539. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*